[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Caribou Biosciences Inc (CRBU)

Caribou Biosciences Inc (CRBU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 182,493
  • Shares Outstanding, K 99,181
  • Annual Sales, $ 11,160 K
  • Annual Income, $ -148,130 K
  • EBIT $ -132 M
  • EBITDA $ -129 M
  • 60-Month Beta 2.33
  • Price/Sales 16.35
  • Price/Cash Flow N/A
  • Price/Book 1.78

Options Overview Details

View History
  • Implied Volatility 203.81% (+30.51%)
  • Historical Volatility 70.68%
  • IV Percentile 60%
  • IV Rank 31.05%
  • IV High 457.33% on 02/12/26
  • IV Low 89.62% on 05/29/26
  • Expected Move (DTE 7) 0.3825 (21.37%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 18
  • Volume Avg (30-Day) 497
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 8,994
  • Open Int (30-Day) 7,885
  • Expected Range 1.4075 to 2.1725

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.33
  • Number of Estimates 3
  • High Estimate $-0.29
  • Low Estimate $-0.38
  • Prior Year $-0.35
  • Growth Rate Est. (year over year) +5.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7700 +1.13%
on 06/10/26
2.4900 -28.11%
on 06/01/26
-0.1500 (-7.73%)
since 05/08/26
3-Month
1.6850 +6.23%
on 03/30/26
2.4900 -28.11%
on 06/01/26
-0.2400 (-11.82%)
since 03/10/26
52-Week
1.0400 +72.12%
on 06/16/25
3.5400 -49.44%
on 11/03/25
+0.5700 (+46.72%)
since 06/10/25

Most Recent Stories

More News
Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference

BERKELEY, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences , Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz,...

CRBU : 1.7900 (-2.72%)
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference

BERKELEY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences , Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that Caribou’s...

CRBU : 1.7900 (-2.72%)
Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting

BERKELEY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences , Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts...

CRBU : 1.7900 (-2.72%)
Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

-- Achieved alignment with FDA on pivotal ANTLER-3 trial design for vispa-cel in 2L LBCL -- -- Longer follow up on vispa-cel phase 1 clinical data expected at medical conference in 2026 -- --...

CRBU : 1.7900 (-2.72%)
Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference

BERKELEY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences , Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz,...

CRBU : 1.7900 (-2.72%)
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy

-- RMAT granted based on promising initial clinical data, including previously disclosed recommended dose for expansion data of 92% ORR, 75% ≥CR rate, 91% MRD negativity in the 12-patient, BCMA-naïve...

CRBU : 1.7900 (-2.72%)
Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

BERKELEY, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences , Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results...

CRBU : 1.7900 (-2.72%)
Caribou Biosciences to Participate in Upcoming Investor Conferences

BERKELEY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will...

CRBU : 1.7900 (-2.72%)
Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®

Clinical data disclosed in November 2025 to be presented at medical meeting with new supportive translational data for both programs Vispa-cel (CB-010) ANTLER phase 1 translational and clinical...

CRBU : 1.7900 (-2.72%)
Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025

KOL panel to discuss how vispa-cel, an anti-CD19 allogeneic CAR-T cell therapy, can broaden access for patients with second-line large B cell lymphoma including through use in the community setting ...

CRBU : 1.7900 (-2.72%)

Business Summary

Caribou Biosciences Inc. is a clinical-stage CRISPR genome-editing biopharmaceutical company. It involved in developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors. Caribou Biosciences Inc. is based in...

See More

Key Turning Points

3rd Resistance Point 1.9667
2nd Resistance Point 1.9233
1st Resistance Point 1.8567
Last Price 1.7900
1st Support Level 1.7467
2nd Support Level 1.7033
3rd Support Level 1.6367

See More

52-Week High 3.5400
Fibonacci 61.8% 2.5850
Fibonacci 50% 2.2900
Fibonacci 38.2% 1.9950
Last Price 1.7900
52-Week Low 1.0400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.